Nature Medicine Retracts Viral Lung Cancer Timing Study After Four-Month Investigation

Nature Medicine has retracted a widely circulated study claiming that the time-of-day patients received immunochemotherapy significantly affected survival outcomes in non-small cell lung cancer (NSCLC). The retraction, issued June 24, follows a four-month investigation into the integrity of the trial, known as LungTIME-C01.¹

"Due to the amount and nature of the problems identified, the editors no longer have confidence in the integrity of the results," the retraction note states.²

A study that moved fast

When the paper first appeared in Nature Medicine on February 2, it generated immediate and widespread attention. The trial, conducted at Hunan Cancer Hospital in China, reported that NSCLC patients who received the first four cycles of immunochemotherapy before 3 p.m. had a median progression-free survival (PFS) of 11.3 months, compared with 5.7 months for those treated after 3 p.m. Median overall survival was 28.0 months in the early group versus 16.8 months in the late group.

The PD-1 drugs used were either Merck's Keytruda (pembrolizumab) or Innovent Biologics' Tyvyt (sintilimab). According to Fierce Pharma, within days of publication, prominent physician-scientist Eric Topol had flagged the study to his more than 700,000 followers on X as "probably the best proof of the importance of timing of therapy that we've seen in medicine to date."³

By February 19, Nature Medicine had posted an editorial alert flagging concerns with the results. Not everyone was swept up in the initial enthusiasm.

In separate interviews with Fierce Pharma, two experts offered more measured takes. Charu Aggarwal, MD, who leads the head and neck and thoracic cancers practice at Penn Medicine, called the magnitude of benefit somewhat surprising and said the results would warrant careful consideration and international multicenter validation.

Leerink Partners analyst Daina Graybosch, PhD, described the study as hypothesis-generating given that it came from a single center, though she acknowledged its prospective, randomized design and large effect size gave it unusual weight.

What the investigation found

The problems identified during the investigation fell into two broad categories: documentation inconsistencies and unusual data patterns.

On the documentation side, the trial's ClinicalTrials.gov registration record showed multiple major mid-trial design changes following its 2022 launch, including switching the study type between interventional and observational in 2024, altering primary and secondary endpoints, and nearly overhauling enrollment criteria.

The protocol published as a supplement to the paper was dated January 2022 but contained references to articles published in 2022, 2023, and 2024. Investigators also found discrepancies between the original Chinese-language protocol and the translated versions provided during peer review and for publication.

The authors attributed these issues largely to administrative errors rather than prospectively documented amendments—an explanation the editors ultimately did not find sufficient. The data patterns raised separate concerns.

The PFS curve appeared smoother than is typically observed in similar Phase III trials, in which fixed imaging intervals usually produce a staircase-like shape. The trial recorded zero censoring in the first year, meaning every patient was tracked and remained on treatment throughout the entire period. There were also no adverse events leading to treatment discontinuation in either arm across the entire trial.

Additionally, the two arms showed similar rates of immune-related adverse events despite the substantial differences in efficacy between them—a finding that drew scrutiny given the authors' claim that shifts in T-cell subpopulations partly explained the survival difference.

Compounding everything else, the source data provided by the authors showed that randomization was performed on the day of treatment for almost all patients, which is a practice the retraction note described as uncommon. Further, the authors acknowledged deviations from fixed-calendar imaging schedules due to COVID-19, indicating a lack of adherence to standard RECIST timing.

Where the science stands

The retraction does not eliminate the underlying biological hypothesis. Circadian immunology—the idea that immune cells are more active during daylight hours and better primed to mount cytotoxic responses—has support from multiple retrospective studies, including a March 2026 analysis in Blood linking morning CAR T-cell infusion to higher one-year PFS in large B-cell lymphoma patients.

But as Graybosch noted before the retraction, the long half-life of anti-PD-1 antibodies—Keytruda persists in the body for more than 20 days, for example—makes it difficult for many experts to accept that administration timing could drive such dramatically different outcomes. The LungTIME-C01 findings, she said, would need to be validated in well-designed international studies with translational data before any conclusions about mechanism could be drawn.

According to the retraction note, the study's corresponding authors agreed with the retraction. Several other authors did not respond to correspondence from Nature Medicine.

References

1. Nature Retracts Cancer Study Suggesting Treatment Is Better Earlier in the Day. MedPage Today. June 24, 2026. Accessed June 25, 2026. https://www.medpagetoday.com/hematologyoncology/lungcancer/121913

2. Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial. Zhe Huang, et al. Nature Medicine. June 24, 2026. Accessed June 25, 2026. https://www.nature.com/articles/s41591-026-04508-1

3. Nature retracts provocative PD-1 study that tied lung cancer survival to treatment timing. Fierce Pharma. June 24, 2026. Accessed June 25, 2026. https://www.fiercepharma.com/pharma/nature-retracts-provocative-pd-1-study-tied-lung-cancer-survival-treatment-timing